News & Events
Published On: 9/9/2020
Asian Lean Patients With NAFLD Are 53% Less Likely To Have Cirrhosis, Cardiovascular, And Metabolic Diseases - Latest Data Findings Released From TARGET-NASH Study
DURHAM, N.C., Sept. 9, 2020 /PRNewswire/ -- Target RWE, an innovative health evidence solutions company generating real-world evidence (RWE) and delivering regulatory-grade data, announced the latest findings from its nonalcoholic steatohepatitis (NASH) clinical study TARGET-NASH.
Published in Clinical Gastroenterology and Hepatology, Asian patients with a lean body mass index (BMI) category and nonalcoholic fatty liver disease (NAFLD) are 53% less likely to have a more severe form of liver disease compared to non-Asian NAFLD participants with lean BMI.
"These findings can help direct our research into why there is a disparity between lean NAFLD patients of different ethnic origins and the long-term clinical implications of NAFLD in people who clinically present as lean," said Ethan Weinberg, MD, MS, Assistant Professor of Clinical Medicine at the University of Pennsylvania School of Medicine, and lead author. "This is further evidence that NAFLD is not a homogenous disease and the severity is influenced by a number of factors other than simply having fat in the liver."
"We know there are differences in genetics, often covering a wide geographic area for people of Asian descent, and factors like diet and lifestyle, that contribute to a NAFLD diagnosis. This observational research provides valuable insights into populations who might not be adequately represented in a traditional clinical trial."
The study analyzed 3,386 participants with NAFLD enrolled in TARGET-NASH from August 2016 to March 2019. The objective was to describe the prevalence of cirrhosis among patients with NAFLD and normal BMI, as NAFLD is typically associated with obesity.
"As expected, we found that most patients with NAFLD were overweight or obese and only 13% had normal BMI (lean NAFLD). Across all races and ethnicities, NAFLD patients with normal BMI were less likely to have cirrhosis, cardiovascular, or metabolic diseases than those who are obese," said Anna Lok, MD, Professor of Medicine at the University of Michigan, and senior author. "Even so, we need to help NAFLD patients with normal BMI to get rid of the fat in their liver and to understand if their liver, cardiovascular, and metabolic diseases progress at slower rates than those who are obese."
TARGET-NASH is an observational study of participants with NAFLD and/or NASH in usual clinical practice. Target RWE's network of sites includes adult and pediatric participants, across the disease spectrum, receiving care in community and academic centers. Once enrolled, three years of retrospective and five years of prospective data is collected.
About Target RWE
As the industry's best-in-class, complete real world evidence (RWE) solution, Target RWE is a distinctly collaborative enterprise that unifies real world data (RWD) sets and advanced RWE analytics in an integrated community, shifting the paradigm in healthcare for how decisions are made to improve lives.
Target RWE sources unique, connected data sets across multiple therapeutic areas representing granular data from diverse patients in academic and community settings. Our rigorous, interactive, and advanced RWE analytics extract deep insights from RWD to answer important questions in healthcare. Target RWE brings together the brightest minds in healthcare through an unmatched community of key opinion leaders, patients, and healthcare stakeholders in a collaborative and dynamic model. www.targetrwe.com
984.234.0268 ext 205
01/11/2023Target RWE Launches 35 New Disease State Registries in Complex Indications with High Unmet Medical Needs and Rapidly Evolving Therapies
11/04/2022New TARGET-NASH Real World Data Show Non-Alcoholic Fatty Liver Disease Severity and Gender Linked to Disparities in Polypharmacy
10/18/2022Target RWE and the American Association for the Study of Liver Diseases Announce Research Agreement for Cirrhosis Quality Collaborative
08/25/2022New Approaches for Developing Real-World Evidence Presented by Target RWE at the 2022 International Conference on Pharmacoepidemiology (ICPE)
08/24/2022Durham-Based Target RWE Grows Data Abstraction, Curation Capabilities with Latest Acquisition